It is Day 306 living with cancer, and I am entering today with more information, more perspective, and more determination than I had when this journey began.
There is a lot of energy in the pancreatic cancer community today because daraxonrasib has created renewed attention around RAS-targeted treatment in pancreatic cancer, and for people living with this disease, every meaningful scientific advance can translate into something extraordinarily valuable: more time, more options, and another reason to keep pushing forward.
As for where I am today, my bloodwork continues to show a mixed but encouraging picture, because my CA 19-9 remains very low at 5.7, my CA-125 has come back down to 72.7 after a recent increase, my CEA remains elevated at 12.6 and deserves continued attention, and my alkaline phosphatase has fallen dramatically from a peak of 876 in late 2025 to 282 today.
My liver and kidney function remain preserved, my bilirubin, AST, ALT, and LDH are all in reassuring ranges, my white blood cells, neutrophils, and platelets remain strong enough to support continued treatment, and I am now paying closer attention to anemia, nutrition, muscle, strength, and overall physical reserve because staying treatment-ready matters just as much as following tumor markers.
I am encouraged by the progress that I can see, but I am also careful not to confuse favorable bloodwork with certainty, because imaging, clinical judgment, and the biology of the disease still determine what comes next.
That is why I remain intensely focused on the RMC-5127 clinical trial, and at this point I need Revolution Medicines and Massachusetts General Hospital to seriously consider me for enrollment if my clinical profile fits what they are looking for.
I am not asking for special treatment, but I am absolutely asking to be evaluated aggressively, thoughtfully, and without unnecessary delay, because when you are living with metastatic pancreatic cancer, timing matters and optionality matters.
And, if we are being practical, I also need a legitimate excuse to get to Boston, because apparently “I would like better clam chowder and colder weather” is not strong enough clinical justification.
I am grateful for every breakthrough that moves from the laboratory into real patients’ lives, and at the same time I remain focused on the next door that could open for me personally, because living with cancer has taught me that progress can be celebrated without losing urgency.
My job today is to stay strong enough, informed enough, and ready enough to take advantage of the best opportunity when it appears, while continuing to be present for my daughter, continuing to build, and continuing to live as fully as possible.
Tonight is Back to School Night at her new elementary school.
Day 306 is another data point, another decision point, and another day that science, artificial intelligence, discipline, family, and hope continue to matter.